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Abstract
Background: subclinical hyperthyroidism (SHT) is as-
sociated with harmful effects on cardiovascular system, 
bone metabolism and progression to clinical hyperthyroi-
dism. 
 Loss of weight is a common fact in patients with clini-
cal hyperthyroidism and of particular relevance in elder-
ly patients.
Objective: to assess changes in body composition after 
radioiodine therapy for SHT due to toxic nodular goiter.
Subjects and methods: prospective controlled cohort 
study. Patients with persistent SHT due to toxic nodu-
lar goiter were purposed to receive treatment with ra-
dioiodine (treatment group) or to delay treatment until 
the study was over (control group). All treated patients 
received 555 MBq of 131I. 
 Body composition (lean mass, fat mass and bone mi-
neral content) was determined by dual-energy X-ray ab-
sorptiometry (DEXA) at baseline and 12 months after.
Results: twenty-nine patients were studied (age 
69.5 ± 11.5; 75.9% women; BMI 27.1 ± 5.7 kg/m²; serum 
thyrotropin (TSH) 0.20 ± 0.21 µUI/mL; serum free thyro-
xine (T4) 1.01 ± 0.19 ng/dL), 17 belonging to the treat-
ment group and 12 to the control group. 
 Study groups were comparable, although there was a 
trend for the treatment group to have more fat mass. 
 No longitudinal changes in body composition were noted 
in either group, except for a trend to gain fat mass. Howe-
ver, when individuals with age > 65 years were selected, 
only patients who received radioiodine therapy showed 
a significant increase in body weight (from 64.1 ± 10.0 to 
66.9 ± 9.2 kg), BMI (from 27.3 ± 4.8 to 28.7 ± 4.5 kg/m²), 
fat mass (from 26.1 ± 8.5 to 27.8 ± 7.9 kg), lean mass (from 
36.3 ± 0.4 to 37.4 ± 0.4 kg) and skeletal muscle mass index 
(SMI) (from 6.0 ± 0.6 to 6.3 ± 0.6 kg/m²). 
TRATAMIENTO DEL HIPERTIROIDISMO 
SUBCLÍNICO: EFECTO SOBRE LA 
COMPOSICIÓN CORPORAL
Resumen
Introducción: el hipertiroidismo subclínico (HS) se 
asocia a efectos deletéreos sobre el sistema cardiovas-
cular, el metabolismo óseo y puede progresar a hiperti-
roidismo clínico. La pérdida de peso es habitual en los 
pacientes con hipertiroidismo clínico y adquiere especial 
relevancia en los sujetos añosos.
Objetivo: evaluar los cambios en la composición cor-
poral después del tratamiento del HS por bocio nodular 
con radioyodo.
Sujetos y métodos: estudio de cohortes prospectivo 
controlado. A los pacientes con HS persistente debido a 
bocio nodular tóxico se les ofreció la opción de recibir 
tratamiento con radioyodo (grupo tratamiento) o retra-
sar dicho tratamiento hasta que el estudio hubiera acaba-
do (grupo control). Al final, todos los pacientes recibieron 
555 MBq de 131I.
 La composición corporal (masa magra, masa grasa y 
contenido mineral óseo) se determinó por absorciometría 
con rayos X de doble energía (DEXA) al inicio y a los 
12 meses.
Resultados: se estudiaron 29 pacientes (edad 
69,5 ± 11,5; 75,9% mujeres; BMI 27,1 ± 5,7 kg/m²; tiro-
tropina sérica (TSH) 0,20 ± 0,21 µUI/mL; tiroxina libre 
sérica(T4) 1,01 ± 0,19 ng/dL), 17 pertenecientes al grupo 
tratamiento y 12 al grupo control. 
 Los grupos de estudio fueron comparables, aunque 
existía una tendencia del grupo tratamiento a presentar 
más masa grasa. No se detectaron cambios en la com-
posición corporal en ningún grupo, salvo una tendencia 
general a ganar masa grasa. Sin embargo, cuando se se-
leccionaron los individuos con edad > 65 años, sólo los 
pacientes que recibieron tratamiento con radioyodo mos-
traron un significativo incremento de peso (de 64,1 ± 10,0 
a 66,9 ± 9,2 kg), IMC (de 27,3 ± 4,8 a 28,7 ± 4,5 kg/m²), 
masa grasa (de 26,1 ± 8,5 a 27,8 ± 7,9 kg), masa magra 
(de 36,3 ± 0,4 a 37,4 ± 0,4 kg) e índice de masa muscular 
esquelética (de 6,0 ± 0,6 a 6,3 ± 0,6 kg/m²).Correspondence: Diana Boj-Carceller. 
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Abbreviations
SHT: subclinical hyperthyroidism.
OHT: overt hyperthyroidism.
DEXA: dual-energy X-ray absorptiometry.
TSH: serum thyrotropin.
T4: serum free thyroxine.
T3: serum free triiodothyronine.
SMI: skeletal muscle mass index.
BMD: bone mineral density.
FM: fat mass.
MM: lean mass.
BIA: bioelectrical impedance analysis.
RAI: radioiodine.
rs: Spearman’s correlation coefficient.
Introduction
Subclinical hyperthyroidism (SHT) is defined by a 
low serum thyrotropin (TSH) level, under the referen-
ce range (0.45 to 4.5 mIU/L), and normal serum free 
thyroxine (T4) and/or triiodothyronine (T3) levels.
The prevalence depends on age, sex and iodine in-
gestion. In the NHANES III survey1, SHT was foun-
ded in 0.7% of the U.S. population (excluding those 
taking thyroid replacement therapy). 
In elderly people, toxic nodular goiter is the most 
prevalent etiology of endogenous SHT2. Endogenous 
SHT might have more clinical impact than exogenous 
SHT because of its chronic character and higher levels 
of T33. 
The main related adverse effects of SHT include 
cardiovascular disease, with increase risk of atrial 
fibrillation4,5 and cardiovascular death6,7, but also 
all-cause mortality7. 
The risk of progression to overt hyperthyroidism 
(OHT) varies between studies 1-15% / year, depending 
on the concentration of TSH (high probability if the 
serum TSH is suppressed) and the underlying patholo-
gy (most likely if the cause is nodular goiter)8.
In most studies, postmenopausal women with SHT 
have bone mineral density (BMD) decreased, especia-
lly at the cortical bone9,10. There is less data on these 
effects in men and premenopausal women. 
Sarcopenia, whose concept includes loss of lean 
mass, is a relevant clinical problem in elderly people 
with risk of adverse outcomes such as physical disa-
bility, poor quality of life and mortality11. Causes of 
secondary sarcopenia also include hyperthyroidism. 
It is well known that OHT is associated with loss of 
weight, despite of an increase in the caloric content of 
the diet and the recovery of the euthyroidism status is 
associated with weight gain.
However, changes in body composition following 
treatment of OHT have been hardly studied. 
The results presented so far are rather mixed. Some 
authors have shown that bone mass, fat mass (FM) and 
lean mass (MM) increase in parallel12.
Lönn et al. described that initially after treatment, 
patients recovered only MM, but at 12 months it was 
also found an increase in FM13.Whilst, other groups 
have reported that weight gain reflects only increments 
of the MM14,15. Two studies using methodology based 
on the BIA showed only increases in FM16,17 (Table I).
In the case of SHT, only one work has addressed 
this issue18. Greenlund et al. studied 21 women with 
SHT who were treated with high doses of radioiodi-
ne (RAI) and reevaluated after 6 months of normal 
thyroid function. Fat free-mass determined by DEXA 
increased from a mean of 40.3 Kg to 42.2 Kg and FM 
increased in a similar magnitude. BMD also increased 
in a significant way. 
The indications for treatment of SHT are matter of 
discussion, but in elderly individuals, despite of the 
absence of supportive data from intervention trials19, 
clinicians might consider treatment due to the possible 
cardiovascular risk. In this context, RAI therapy is a 
definitive, safe and effective option of treatment.
Further investigation of the impact of SHT on body 
composition is required, specially in older people, 
where the probability of clinical adverse outcomes is 
higher. The aim of our study was to assess changes in 
body composition after radioiodine therapy for SHT 
due to toxic nodular goiter.
Material and methods
Thirty-one patients with endogenous SHT due to 
nodular goiter were recruited prospectively over a 
21-months period in the outpatient endocrinology unit 
of a tertiary referral hospital.
Inclusion criteria were older than 18 years, both 
sexes, persistent endogenous subclinical hyperthyroi-
dism, nodular goiter (including toxic multinodular 
Conclusions: treatment of SHT has impact on body 
composition in subjects older than 65 years. Weight gain 
reflects increases in fat and, more interestingly, in lean 
mass.
(Nutr Hosp. 2015;32:2331-2337)
DOI:10.3305/nh.2015.32.5.9660
Key words: Subclinical hyperthyroidism. Body composi-
tion. Radioiodine. Goiter. Hyperthyroidism.
Conclusiones: el tratamiento del HS tiene impac-
to sobre la composición corporal en sujetos mayores de 
65 años. La ganancia de peso refleja incrementos en la 
masa grasa y, lo que es más interesante, en la masa magra.
(Nutr Hosp. 2015;32:2331-2337)
DOI:10.3305/nh.2015.32.5.9660
Palabras clave: Hipertiroidismo subclínico. Composición 
corporal. Radioyodo. Bocio. Hipertiroidismo.
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goiter and autonomous nodule) as underlying thyroid 
disease, not have received prior treatment for thyroid 
disease and candidates for treatment with 131I .
Patients were excluded if they refused to participate, 
had a history of previous thyroid surgery, low TSH of 
another etiology , suspicion of malignancy, compres-
sive symptoms, RAI therapy contraindication , serious 
medical illness or weight of loss> 10% in the 6 pre-
vious months.
Criteria for withdrawal were patient desire, 
non-compliance with the study protocol, development 
of clinical hyperthyroidism, appearance of serious ill-
ness or suspicion of malignancy.
The protocol was conducted in accordance with 
Good Clinical Practice and the Declaration of Helsin-
ki. Written informed consent was obtained from all 
participants after the nature of the study procedures 
were explained and prior to conducting any study-re-
lated procedures. 
The diagnosis of SHT due to nodular goiter was ba-
sed on biochemical findings (TSH level under the re-
ference range < 0.34 µUI/mL and normal free T4 and 
T3 levels), technetium thyroid scintigraphy (to identi-
fy autonomous hyperfunctioning nodules) and thyroid 
ultrasound (to define nodules).
This prospective cohort study was designed following 
standard medical practice. Patients were offered the 
option of treatment with RAI (intervention group) or 
post-treatment follow-up at the end of the study, i.e., the 
option to defer RAI treatment (control group). 
All patients received a single standard dose of 131I of 
15 mCi (555 MBq).
Body Composition 
Assessment of lean mass, fat mass and bone mine-
ral density was made at baseline and at the end of the 
study (12 months) using dual-energy x-ray absorptio-
metry scanning on a Hologic QDR 1000W scanner.
The body mass index (BMI) was calculated from 
the formula BMI = weight (Kg) / height2 (m2).
Body weight (Kg) was determined on a scale Soe-
hnle Professional 2755 model, which has a maximum 
weight of 200 Kg and a precision of 100 g, with the 
patient without shoes and in light clothing. Height 
(cm) was measured with the metal stadiometer Asi-
med, whose measurement range is from 95 to 200 cm 
and has a precision of 1 mm, with the patient standing, 
fully stretched, placing feet in parallel.
The skeletal muscle mass index (SMI) was calcu-
lated as the sum of the muscle mass of the four limbs 
determined by DEXA divided by height (m2).
Serum TSH and Thyroid Hormone Assays
Serum TSH was measured using a third generation 
automated sandwich 2-site chemiluminometric im-
munoassay (Bayer Advia, East Walpole, Massachu-
setts).
Serum T4 was measured by the direct dialysis me-
thod (Bayer Advia, East Walpole, Massachusetts).
Serum T3 was measured using an automated chemi-
luminometric immunoassay (Bayer Advia, East Wal-
pole, Massachusetts).
Statistical methods
The Mann-Whitney U-test was used to test if groups 
were initially comparable. Within each group, before 
and after treatment measurements were compared 
using Wilcoxon Signed Rank Test. 
Fisher’s exact test was used to compare thyroid sta-
tus between groups at the end of study. 
The correlation between age and changes in body 
composition was determined by the Spearman’s corre-
lation coefficient (rs).
A p value <0.05 was considered to be statistically 
significant.
Data are presented as mean ± standard deviation.
The statistical analyses of our study was performed 
using SPSS statistical software version 17.0.
Table I 
Studies assessing body composition of hyperthyroid subjects before and after treatment
n
predominant 
disease method FM (Kg) MM (Kg) BM (Kg)
Time 
evolution Reference
Zimmermann et al. (1998) 10 GD DEXA + 4.0 + 5.0 n.e. 12 months (12)
Lönn et al. (1998) 9 GD DEXA + 3.5 + 5.3 no 12 months (13)
De la Rosa et al. (1997) 9 n.e. DEXA no + 7.2 no 13 months (14)
Gómez-Acotto et al. (2002) 10 GD DEXA no + 1.9 no 24 months (15)
Jacobsen et al. (2006) 8 n.e. BIA + 3.5 no - 12 months (16)
P. Iglesias et al. (2006) 29 GD BIA + 4.5 no - n.e. (17)
n, number of patients; n.e., not specified; GD, Graves disease; DEXA, dual-energy X-ray absorptiometry; BIA, bioelectrical impedance analysis; 
FM, fat mass; MM, lean mass; BM, bone mass; no, no changes.
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Results
Twenty-nine patients were finally included. Two pa-
tients in the treatment group were withdrawn because 
of non-compliance with the study protocol. 
Population baseline characteristics (Table II) were 
age 69.5±11.5; 75.9% women (menopausal sta-
tus did not change during the study in any patient); 
BMI 27.1±5.7 Kg/m²; TSH 0.20±0.21 µUI/mL; T4 
1.01±0.19 ng/dL. Most patients had multinodular goi-
ter (just one case in the control group had a solitary 
autonomous nodule in scintigraphy and ultrasound). 
Time from first blood test showing hyperthyroidism 
was very variable. 
There were no difference in body composition be-
tween groups, although there was a trend for the treat-
ment group to have more fat mass (+ 5.0 Kg, p=0.051). 
One year after RAI therapy, SCH was resolved in 
most (94.1%) patients, and “hypothyroidism” (low 
T4 with normal TSH) was mild and temporary in two 
patients at 4 and 8 months, respectively (5.9%). One 
(5.9%) of the treated patients progressed to overt mild 
hyperthyroidism at the end of the study and received 
again another dose of 15 mCi of 131I. 
In the control group, two (16.7%) patients finished 
the study with normal thyroid function, while two 
(16.7%) patients progressed to T3 thyrotoxicosis and 
eight (66.7%) maintained SHT .
Within each group, the statistical analysis for the 
comparisons before and after did not show significant 
differences (Table III). A trend to gain FM was obser-
ved in both groups (+1.3 Kg in the control group and 
+0.5 Kg in the treatment group). 
In the treatment group, age correlated significant-
ly with changes in body composition: weight gain 
(rs=0.692, p=0.002), BMI gain (rs=0.705, p=0.002), 
MM gain (rs=0.615, p=0.009) and with skeletal mus-
cle mass index (SMI) change (rs=0.644, p=0.005) 
(Fig. 1). In contrast, in the control group age did not 
correlate with any change in body composition.
A subgroup analysis selecting individuals with age 
>65 was performed. 
Only patients who had received RAI therapy showed 
a significant increase in body weight (from 64.1±10.0 
to 66.9±9.2 Kg), BMI (from 27.3±4.8 to 28.7±4.5 Kg/
m²), FM (from 26.1±8.5 to 27.8±7.9 Kg), MM (from 
36.3±0.4 to 37.4±0.4 Kg) and SMI (from 6.0±0.6 to 
6.3±0.6 Kg/m²) (Table IV). 
Discussion
No changes were found in body composition after 
treatment of SHT in the whole population study. This 
result contrasts with the studies mentioned in the in-
troduction12-16. They did find differences with a smaller 
Table II 
Baseline characteristics of the study population
control group (n=12) treatment group (n=17) p value
age (years) 67.0 ± 12.0 71.2 ± 11.2
sex (male/female) 3/9 4/13
TSH (µUI/mL) 0.26 ± 0.27 0.15 ± 0.16 0.325
T4 (ng/dL) 1.0 ± 0.2 1.0 ± 0.2 0.711
T3 (pg/mL) 3.4 ± 0.6 3.4 ± 0.5 0.478
premorbid weight (Kg) 67.7 ± 21.1 71.8 ± 12.5 0.327
weight (Kg) 63.9 ± 21.3 69.5 ± 13.1 0.156
height (cm) 157.9 ± 10.3 157.7 ± 9.4 0.875
BMI (Kg/m2) 25.9 ± 7.2 27.9 ± 4.4 0.184
FM (Kg) 22.3 ± 13.5 27.3 ± 8.5 0.051
MM (Kg) 39.9 ± 10.0 40.4 ± 9.4 0.626
BM (Kg) 1.8 ± 0.5 1.9 ± 0.6 0.690
BMD (g/cm2) 1.01 ± 0.1 1.2 ± 0.5 0.658
t score -1.3 ± 1.2 -0.8 ± 1.6 0.492
% FM 33.2 ± 9.0 39.0 ± 8.6 0.092
SMI (Kg/m2) 6.6 ± 1.3 6.5 ± 1.2 0.866
TSH, serum thyrotropin; T4,serum free thyroxine; T3,serum free triiodothyronine; BMI, body mass index; FM, fat mass; MM, lean mass; BM, 
bone mass; BMD, bone mineral density; SMI, skeletal muscle mass index.
Mean ± S.D. and the proportion are shown where appropriate.
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sample size. There could be several explanations for 
this fact.
All studies, except the Greenlund et al.18, included 
only patients with OHT. The present study has eva-
luated the effect of treatment of SHT, that represents a 
milder degree of thyroid dysfunction, so it was expec-
ted that the effect size was the same.
Graves disease is the most prevalent pathology in all 
the studies. This thyroid disease is metabolically more 
active than toxic nodular goiter, which also may have 
influenced the magnitude of the differences.
The body composition analysis method used in the 
other studies has not always been the gold standard, 
so that the results are not always validated from the 
methodological point of view.
It is necessary to consider possible confounding 
variables (besides sex and age) when interpreting 
changes in body composition such as prevalence of 
obesity (30% in our study), previous weight loss rela-
ted to SHT (-2.7 Kg in the control group and -0.1 Kg 
in the treatment group), duration of hyperthyroidism 
(330 days in the control group and 422 days in the 
treatment group) or development of hypothyroidism 
after RAI (2 cases of transient hypothyroidism in our 
study). These have not always been reported in all stu-
dies.
Only a trend to gain FM over time was observed in 
both groups (+ 1.3 Kg in the control group, p=0.084, 
and + 0.5 Kg in the treatment group, p=0.093), which 
could be a physiological phenomenon in the aging pro-
cess. 
The effect of age was analyzed as one of the typical 
confusion variable and a key factor for the indication 
of treatment in specific clinical situations8. 
Table III 
Longitudinal changes in body composition 
Control Group Treatment Group
before (n=12) after (n=12) p value before (n=17) after (n=17) p value
weight (Kg) 63.9 ± 21.3 65.4 ± 20.8 0.272 69.5 ± 13.1 70.2 ± 10.3 0.227
height (cm) 157.9 ± 10.3 156.5 ± 12.4 0.400 157.7 ± 9.4 157.3 ±9.5 0.229
BMI (Kg/m2) 25.9 ± 7.2 26.7 ± 6.9 0.084 27.9 ± 4.4 28.4 ± 3.7 0.124
FM (Kg) 22.3 ± 13.5 23.6 ± 13.2 0.084 27.3 ± 8.5 27.8 ± 6.8 0.093
MM (Kg) 39.9 ± 10.0 40.0 ± 10.4 0.875 40.4 ± 9.4 40.5 ± 7.8 0.407
BM (Kg) 1.8 ± 0.5 1.8 ± 0.5 0.136 1.9 ± 0.6 1.9 ± 0.5 0.943
BMD (g/cm2) 1.0 ± 0.1 0.8 ± 0.7 0.937 1.2 ± 0.5 1.0 ± 0.2 0.679
t score -1.3 ± 1.2 - 1.3 ± 1.1 0.722 -0.8 ± 1.6 -0.8 ± 1.3 0.682
% FM 33.2 ± 9.0 34.7 ± 8.9 0.136 39.0 ± 8.6 39.5 ± 7.2 0.309
SMI (Kg/m2) 6.6 ± 1.3 6.5 ± 1.4 0.929 6.5 ± 1.2 6.5 ± 0.9 0.619
BMI, body mass index; FM, fat mass; MM, lean mass; BM, bone mass; BMD, bone mineral density; SMI, skeletal muscle mass index. Mean ± 
S.D.
Fig. 1.—Scatter plot of age and changes of lean mass (difference before-after follow up) in each group.
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In the treatment group, age correlated significantly 
with weight gain (rs=0.692, p=0.002), BMI (rs=0.705, 
p=0.002), MM gain (rs=0.615, p=0.009) and improve-
ment of SMI (rs=0.644, p=0.005). In the control group 
these correlations were not observed.
When only individuals age > 65 were selected, pa-
tients who have received RAI exhibited a significant 
gain of weight, BMI, FM and MM. The percentage of 
FM remained constant because the weight gain was 
the result of FM and MM gain. 
The gain of MM and FM in this study was lower 
than in the Greenlund et al.18. Besides, bone mine-
ral density (BMD) was unchanged in our study. It is 
unknown whether monitoring time beyond 12 months 
would yield positive data on bone mineralization. The 
fact that the control group has not changed its BMD 
down as expected over time makes prudent to extend 
the monitoring period at least another year. 
The international guidelines for the management of 
SHT20 consider the positive effect of restoring euthyroi-
dism on bone metabolism in postmenopausal women. 
This is based on two studies. Mudde et al.21 found that 
distal forearm BMD, expressed as a percentage of the 
base-line value, was significantly (P<0.05) higher in pa-
tients who had received treatment for SHT at 24 mon-
ths after therapy. Faber et al.22 found that spine and hip 
BMD of patients who received RAI (the median dose of 
131I administered was the same as in our study) did not 
go down over time, in contrast with the control group 
where patients experimented an annual loss of 2%.
The qualitative results obtained in this work in ter-
ms of increments of FM and MM are consistent with 
those reported by Lonn et al.13 in patients with OHT . 
However, changes in the latter were higher, the sample 
size was the third part and the predominant patholo-
gy was different. In their study, DEXA showed as FM 
did not increase at 3 months, but it did at 12 months. 
Computerized Tomography scan was also used and 
detected an increase in intraperitoneal adipose tissue 
at 3 months, whereas at 12 months subcutaneous adi-
pose tissue also increased. Similarly, DEXA detected 
an early increase in MM. The bone mineral content 
showed no improvement and this was attributed to a 
small sample size. Authors concluded that during the 
first months after normalization of thyroid function, 
the priority is to refill body skeletal muscle and intra-
peritoneal adipose tissue, whereas subcutaneous adi-
pose tissue increases thereafter.
Several studies support from a physiological pers-
pective the former changes in body composition af-
ter treatment of SHT. Martin et al.23 demonstrated 
that hyperthyroidism accelerates protein catabolism 
(+12%) and the oxidation of amino acids (+24%), whi-
le protein synthesis increases only slightly (9%), resul-
ting in a net loss of protein. Lipid accumulation during 
recovery of hyperthyroidism appears to be related with 
the decrease in lipolysis24 because it has been shown 
that the activity of lipoprotein lipase in this situation 
does not increase25. Also, during treatment of hyper-
thyroidism, MM and body mineral content increase 
judging by potassium26 and calcium27 measurements.
Increasing the MM is a clinically relevant fact, espe-
cially in elderly patients. Sarcopenia leads to dysfunc-
tion of the lower extremities, what predisposes to falls, 
which, together with the presence of osteopenia can 
increase the rate of fracture28,29, morbidity and morta-
lity. Gómez-Acotto et al.15 showed that the recovery 
of MM occurred mainly in the limbs and trunk. It has 
not been a purpose of this paper to assess locoregional 
changes in body composition. 
Table IV 
Longitudinal changes in body composition in older individuals 
Control Group Treatment Group
before (n=7) after (n=7) p value before (n=11) after (n=11) p value
weight (Kg) 60.2 ± 13.8 62.3 ± 14.4 0.310 64.1 ± 10.0 66.9 ± 9.2 0.010*
height (cm) 158.5 ± 12.8 157.8 ± 16.9 0.854 153.8 ± 7.9 153.0 ± 7.1 0.124
BMI (Kg/m2) 24.7 ± 4.5 25.4 ± 3.2 0.398 27.3 ± 4.8 28.7 ± 4.5 0.004*
FM (Kg) 18.0 ± 0.7 19.5 ± 0.6 0.237 26.1 ± 8.5 27.8 ± 7.9 0.013*
MM (Kg) 40.4 ± 10.1 41.0 ± 11.1 0.398 36.3 ± 0.4 37.4 ± 0.4 0.033*
BM (Kg) 1.7 ± 0.6 1.8 ± 0.6 0.128 1.6 ± 0.5 1.8 ± 0.4 0.328
BMD (g/cm2) 1.0 ± 0.1 0.7 ± 0.9 0.735 1.2 ± 0.6 1.0 ± 0.1 0.540
t score -1.5 ± 1.4 -1.4 ± 1.4 0.396 -1.0 ± 1.4 -0.9 ± 1.3 0.672
% FM 29.8 ± 8.0 31.4 ± 7.6 0.499 40.1 ± 8.1 41.0 ± 7.0 0.248
SMI (Kg/m2) 6.6 ± 1.2 6.8 ± 1.1 0.600 6.0 ± 0.6 6.3 ± 0.6 0.033*
BMI, body mass index; FM, fat mass; MM, lean mass; BM, bone mass; BMD, bone mineral density; SMI, skeletal muscle mass index.
Mean ± S.D.
*statistically significant result.
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Current international recommendations for the 
treatment of SHT20 are based on the degree of TSH 
suppression, age and patient comorbidities. There is 
an explicit recommendation for treating patients with 
TSH <0.1 and age >65 years, and patients with TSH 
<0.1 and heart disease, osteoporosis and symptoms of 
hyperthyroidism. There is lack of evidence to recom-
mend for or against treatment when TSH is between 
0.1-0.5, but it should be considered in subjects >65 
years and <65 years with heart disease, symptoms of 
hyperthyroidism and menopausal status.
This work opens the door to further prospective stu-
dies, preferably controlled studies, with the purpose 
of setting the indication for treatment of SHT based 
on changes in body composition. The indication when 
TSH is between 0.1-0.5 could be limited to those sub-
jects over 65 years, as it has been the case of treatment 
based on cardiovascular risk assessment and the im-
pact on bone metabolism.
In this study, only treatment of patients over 65 
years has been associated with a significant gain in fat 
mass and, which is more important and interesting, in 
lean mass at 12 months.
Once again, age over 65 years seems to be a factor 
per se to indicate definitive treatment for SHT.
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